The findings of this systematic review are consistent with prior meta-analyses and large-scale trials, which have highlighted the cardiovascular and renal benefits of both SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes [16]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.